Фиброз миокарда — новый компонент ремоделирования сердца у спортсменов?

Исследования по развитию фиброза миокарда являются новым направлением в спортивной медицине. Многочисленные данные свидетельствуют о формировании гипертрофии миокарда, как естественной реакции сердечной мышцы в ответ на систематические физические нагрузки, в то время как появление фиброза у этого контингента не вполне объяснимо. Современные методы визуализации, в т.ч. магнитно-резонансная томография, позволяют выявлять различные варианты фиброза миокарда на субклиническом этапе. В статье рассматриваются различные варианты ремоделирования миокарда и формирования фиброза в зависимости от вида физической нагрузки, механизмы развития последнего, а также методы ранней диагностики, применимые в педиатрической практике. Представлена дифференциальная диагностика ряда патологических состояний, сопровождающихся фиброзом миокарда и возможные направления терапии.

1. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imag. 2015;16(3):233-70. doi:101093/ehjci/jev014.

2. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and reninangiotensin-aldosterone system. Circulation. 1991;83:1849-65.

3. Krenning G, Zeisberg EM, Kalluri R. The origin of fibroblasts and mechanism of cardiac fibrosis. J Cell Physiol. 2010;225:631-7. doi:10.1002/jcp.22322.

4. Rathod RH, Powell AJ, Geva T. Myocardial fibrosis in congenital heart disease. Circulation J. 2016;80: doi:10.1253/circj.CJ-16-0353.

5. Thiene G, Pennelli N, Rossi L. Cardiac conduction system abnormalities as a possible cause of sudden death in young athletes. Hum Pathol. 1983;14(8):704-9.

6. Cocker MS, Strohm O, Smith DJ, et al. Increased Incidence of Myocardial Fibrosis with Reduced Cardiac Function in Elite High-Endurance Athletes: A Cardiovascular Magnetic Resonance (CMR) Study. Circulation. 2008;118:S840.

7. Eijsvogels TMH, Oxborough DL, O'Hanlon R, et al. Global and regional cardiac function in lifelong endurance athletes with and without myocardial fibrosis. Eur J Sport Sci. 2017;17(10):1297-303. doi:10.1080/17461391.2017.1373864.

8. Shiojima I, Sato K, Izumiya Y, et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest. 2005;115:2108-18. doi:10.1172/JCI24682.

9. Lazzeroni D, Rimoldi O, Camici PG. From Left Ventricular Hypertrophy to Dysfunction and Failure. Circ J. 2016;80:555-64. doi:10.1253/circj.CJ-16-0062.

10. Carbone A, D'Andrea A, Riegler L, et al. Cardiac damage in athlete's heart: When the “supernormal” heart fails! World J Cardiol. 2017;9(6):470-80. doi:10.4330/wjc.v9.i6.470.

11. Dawson EA, Whyte GP, Black MA, et al. Changes in vascular and cardiac function after prolonged strenuous exercise in humans. J Appl Physiol. 2008;105:1562-6. doi:10.1152/japplphysiol.90837.2008.

12. Richardson AJ, Leckie T, Watkins ER, et al. Post marathon cardiac troponin T is associated with relative exercise intensity. J Sci Med Sport. 2018;21(9):880-4. doi:10.1016/j.jsams.2018.02.005.

13. Zebrowska A, Waskiewicz Z, Nikolaidis PT, et al. Acute Responses of Novel Cardiac Biomarkers to a 24-h Ultra-Marathon. J Clin Med. 2019;8(1):pii: E57. doi:10.3390/jcm8010057.

14. Virmani R, Robinowitz M, McAllister H. Nontraumatic death in joggers. A series of 30 patients at autopsy. Am J Med. 1982;72:874-82.

15. Rowe WJ. A world record marathon runner with silent ischemia without coronary atherosclerosis. Chest. 1991;99:1306-8.

16. Dlez J, Laviades C, Mayor G, et al. Increased serum concentrations of procollagen peptides in essential hypertension: relation to cardiac alterations. Circulation. 1995;91:1450-6. doi:10.1161/01.CIR.91.5.1450.

17. Каретникова В. Н., Кашталап В. В., Косарева С. Н., Барбараш О. Л. Фиброз миокарда: современные аспекты проблемы. Терапевтический архив. 2017;1:88-93. doi:10.17116/terarkh201789188-93.

18. Woessner JJr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 1991;131:2145-54.

19. Shantsila E, Shantsila A, Blann AD, Lip GY. Left ventricular fibrosis in atrial fibrillation. Am J Cardiol. 2013;111(7):996-1001. doi:10.1016/j.amjcard.2012.12.005.

20. Sasaki N, Okumura Y, Watanabe I, et al. Transthoracic echocardiographic backscatter-based assessment of left atrial remodeling involving left atrial and ventricular fibrosis in patients with atrial fibrillation. Int J Cardiol. 2014;176(3):1064-6. doi:10.1016/j.ijcard.2014.07.138.

21. Mavrogeni S, Papavasiliou A, Giannakopoulou K, et al. Oedema-fibrosis in Duchenne Muscular Dystrophy: Role of cardiovascular magnetic resonance imaging. Eur J Clin Invest. 2017;47(12). doi:10.1111/eci.12843.

22. Simonetti OP, Kim RJ, Fieno DS, et al. An improved MR imaging technique for the visualization of myocardial infarction. Radiology. 2001;218:215-23. doi:10.1148/radiology.218.1.r01ja50215.

23. Flett AS, Hayward MP, Ashworth MT, et al. Equilibrium Contrast Cardiovascular Magnetic Resonance for the Measurement of Diffuse Myocardial Fibrosis: Preliminary Validation in Humans. Circulation. 2010;122:138-44. doi:10.1161/circulationaha.109.930636.

24. Moon JC, Messroghli DR, Kellman P, et al. Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. J Cardiovascular Magnetic Resonance. 2013;15:92. doi:10.1186/1532-429X-15-92.

25. Dzeshka MS, Lip GY, Snezhitskiy V, Shantsila E. Cardiac Fibrosis in Patients With Atrial Fibrillation. JACC. 2015;66 (8):943-59. doi:10.1016/j.jacc.2015.06.1313.

26. Schelbert EB, Piehler KM, Zareba KM, et al. Myocardial Fibrosis Quantified by Extracellular Volume Is Associated With Subsequent Hospitalization for Heart Failure, Death, or Both Across the Spectrum of Ejection Fraction and Heart Failure Stage. J Am Heart Assoc. 2015;4(12). pii: e002613. doi:10.1161/JAHA.115.002613.

27. Mewton N, Liu CY, Croisille P, et al. Assessment of myocardial fibrosis with cardiovascular magnetic resonance. JACC. 2011;57(8):891-903. doi:10.1016/j.jacc.2010.11.013.

28. Van den Borne S, Isobe S, Verjans J, et al. Molecular imaging of interstitial alterations in remodeling myocardium after myocardial infarction. JACC. 2008;52:2017-28. doi:10.1016/j.jacc.2008.07.067.

29. van de Schoor FR, Aengevaeren VL, Hopman MT, et al. Myocardial Fibrosis in Athletes. Mayo Clin Proc. 2016;91(11):1617-31. doi:10.1016/j.mayocp.2016.07.012.

30. Bruder O, Wagner A, Jensen CJ, et al. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. JACC. 2010;56:875-87. doi:10.1016/j.jacc.2010.05.007.

31. Wong TC, Piehler K, Meier CG, et al. Association between extracellular matrix expansion quantified by cardiovascular magnetic resonance and short-term mortality. Circulation. 2012;126:1206-16. doi:10.1161/circulationaha.111.089409.

32. Ichiki T, Huntley BK, Sangaralingham SJ, et al. Atrium fibrosis and inflammation: impaired atrial natriuretic peptide system in experimental heart failure. Circulation. 2014;130: Suppl. 2. A12651.

33. Миклишанская С. В., Мазур Н. А., Шестакова Н. В. Механизмы формирования миокардиального фиброза в норме и при некоторых сердечно-сосудистых заболеваниях. Методы его диагностики. Медицинский Совет. 2017;( 12):75-81. doi:10.21518/2079-701X-2017-12-75-81.

34. Kasner M, Westermann D, Lopez B, et al. Diastolic tissue Doppler indexes correlate with the degree of collagen expression and cross-linking in heart failure and normal ejection fraction. JACC. 2011;57(8):977-85. doi:10.1016/j.jacc.2010.10.024.

35. Mann DL, Bristow MR. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation. 2005;111:2837-49. doi:10.1161/circulationaha.104.500546.

36. Waterhouse DF, Ismail TF, Prasad SK, et al. Imaging focal and interstitial fibrosis with cardiovascular magnetic resonance in athletes with left ventricular hypertrophy: implications for sporting participation. Br J Sports Med. 2012;46 Suppl 1:i69-77. doi:10.1136/bjsports-2012-091482.

37. Breuckmann F, Mohlenkamp S, Nassenstein K, et al. Myocardial late gadolinium enhancement: prevalence, pattern, and prognostic relevance in marathon runners. Radiology. 2009;251(1):50-7 doi:10.1148/radiol.2511081118.

38. Miragoli M, Gaudesius G, Rohr S. Electrotonic modulation of cardiac impulse conduction by myofibroblasts. Circulation Research. 2006;98:801-10. doi:101161/01.RES.0000214537.44195.a3.

39. Biffi A. How to manage athletes with ventricular arrhythmias. Cardiol Clin. 2007;25(3):449-55, vii. doi:10.1016/j.ccl.2007.07.007.

40. Steriotis AK, Nava A, Rigato I, et al. Noninvasive cardiac screening in young athletes with ventricular arrhythmias. Am J Cardiol. 2013;111(4):557-62. doi: 10.1016/j.amjcard.2012.10.044.

41. Стукалова О. В., Апарина О. П., Миронова Н. А., Голицын С. П. Фиброз миокарда левого предсердия по данным магнитно-резонансной томографии с отсроченным контрастированием у больных фибрилляцией предсердий. Альманах клинической медицины. 2015;43:29-37.

42. Kamkin A, Kiseleva I, Lozinsky I. The role of mechanosensitive fibroblasts in the heart: evidence from acutely isolated single cells, cultured cells and from intracellular microelectrode recordings on multicellular preparations from healthy and diseased cardiac tissue. In: Kamkin A, Kiseleva I, editors. Mechanosensitivity of the heart. Mechanosensitivity in cells and tissues. Dordrecht, Heidelberg, London, New York: Springer; 2010. Vol. 3. p. 239-66. ISBN 978-90-481-2850-1.

43. Turagam MK, Velagapudi P, Kocheril AG. Atrial fibrillation in athletes. Am J Cardiol. 2012;109(2):296-302. doi:10.1016/j.amjcard.2011.08.041.

44. Pelliccia A, Maron BJ, Di Paolo FM, et al. Prevalence and clinical significance of left atrial remodeling in competitive athletes. JACC. 2005;46(4):690-6. doi:10.1016/j.jacc.2005.04.052.

45. Mont L, Tamborero D, Elosua R, et al. GIRAFA (Grup Integrat de Recerca en Fibrillacio Auricular) Investigators. Physical activity, height, and left size are independent risk factors for lone atrial fibrillation in middle-aged healthy individuals. Europace. 2008;10:15-20. doi:10.1093/europace/eum263.

46. Swanson R. Atrial fibrillation in athletes: Implicit literature-based connections suggest that overtraining and subsequent inflammation may be a contributory mechanism. Med Hypothesis. 2006;66:1085-92. doi:10.1016/j.mehy.2006.01.006.

47. Rockey DC, Bell PD, Hill JA. Fibrosis — a common pathway to organ injury and failure. New England Journal of Medicine. 2015;372:1138-49. doi:101056/nejmra1300575.

48. Elliott AD, Maatman B, Emery MS, Sanders P. The role of exercise in atrial fibrillation prevention and promotion: Finding optimal ranges for health. Heart Rhythm. 2017;14(11):1713-20. doi:10.1016/j.hrthm.2017.07.001.

49. Diez J, Querejeta R, Lopez B, et al. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation. 2002;105:2512-7.

50. Lopez B, Gonzalez A, Beaumont J, et al. Identification of a potential cardiac antifibrotic mechanism of torsemide in patients with chronic heart failure. JACC. 2007;50:859-67. doi:10.1016/j.jacc.2007.04.080.

51. Ачкасов Е. Е., Машковский Е. В., Богова О. Т. и др. Ремоделирование миокарда при ишемической болезни сердца у ветеранов спорта. Медико-социальная экспертиза и реабилитация. 2013;(4):10-4.

52. Rao Z, Wang S, Bunner WP, et al. Exercise induced Right Ventricular Fibrosis is Associated with Myocardial Damage and Inflammation. Korean Circ J. 2018;48(11):1014-24. doi:10.4070/kcj.2018.0084.